Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy

Figures & data

Table 1 Patient Characteristics

Characteristics (n=69)
Age (years), median (IQR)	71 (57–87)
Male sex, no. (%)	51 (73.9)
ECOG PS score, no. (%)
0	44 (63.8)
≥1	25 (36.2)
Primary tumor site, no. (%)
Upper urinary tract	26 (37.7)
Bladder	24 (34.8)
Upper urinary tract + bladder	19 (27.5)
Pure UC in histologic testing, no. (%)	58 (84.1)
Number of prior chemotherapy regimens before pembrolizumab, no. (%)
1	49 (71.0)
2	11 (15.9)
3	9 (13.1)
Hb <10g/dl, no. (%)	24 (34.8)
Time from previous chemotherapy < 3 months, no (%)	53 (77.9)
Disease site, no. (%)
Lung	32 (46.4)
Lymph node	31 (44.9)
Local recurrence	16 (23.2)
Primary tumor organ (pelvis, ureter and bladder)	14 (20.3)
Liver	13 (18.8)
Bone	7 (10.1)
Subcutaneous	3 (4.3)
Muscle	2 (2.9)
Others	3 (4.3)

Abbreviations: IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group Performance Status; UC, urothelial carcinoma; Hb, hemoglobin.

Table 2 The Objective Response Rate and Disease Control Response Rate in Patients Treated with Pembrolizumab

Response (n=69)	Number of Patients (%)
CR	3 (4.5)
PR	13 (18.8)
SD	12 (17.3))
PD	41 (59.4)
Overall response rate (CR+PR)	16 (23.2)
Disease control rate (CR+PR+SD)	28 (40.6)

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

Table 3 The Organ-Specific Objective Response Rate and Organ-Specific Disease Control Response Rate in Patients Treated with Pembrolizumab

Disease Site	Lung	Lymph Node	Local Recurrence	Primary Organ	Liver	Bone
Number of patients (%)	32 (46.4)	31 (44.9)	16 (23.2)	14 (20.3)	13 (18.8)	7 (10.1)
Number of tumor sites	101	50	16	14	26	19
Median tumor size, mm (IQR)	13 (5–24)	18 (15–22)	39 (21–64)	39 (31–61)	18 (13–33)	19 (13–27)
Organ-specific response rate (CR+PR), %	31.3	29.0	12.5	7.1	23.1	28.6
Organ-specific disease control rate (CR+PR+SD), %	46.8	64.5	43.7	78.6	30.8	85.7
CR, n (%)	5 (15.6)	3 (9.7)	1 (6.2)	0	2 (15.4)	1 (14.3)
PR, n (%)	5 (15.6)	6 (19.3)	1 (6.2)	1 (7.2)	1 (7.7)	1 (14.3)
SD, n (%)	5 (15.6)	11 (35.5)	5 (31.3)	10 (71.4)	1 (7.7)	4 (57.1)
PD, n (%)	17 (53.2)	11 (35.5)	9 (56.3)	3 (21.4)	9 (69.2)	1 (14.3)

Abbreviations: IQR, interquartile range; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

Figure 1 Overall survival in patients treated with pembrolizumab.

Figure 2 Organ-specific overall survival in patients treated with pembrolizumab. *P values are reported.